Multiple societies covering cardiovascular medicine, electrophysiology, heart failure, and imaging have released updated appropriate use criteria (AUC) for various cardiac implantable electronic ...

Please provide your email address to receive an email when new articles are posted on . Major adverse events remained common in patients with nonischemic cardiomyopathy implanted with an electronic ...

Electrophysiologists at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin recently became the first in the U.S. to implant an FDA-approved leadless system for cardiac ...

A Florida hospital has developed a system for wireless real-time monitoring and reprogramming of cardiac devices, including pacemakers and defibrillators, using an iPad. A doctor can suggest changes ...

Medtronic Inc announced the first United States implant of the InSync III Marquis implantable cardioverter-defibrillator (ICD) system and the start of a new clinical trial of the company's newest ...

The opinions expressed herein are the guest's alone and have not been reviewed by a WebMD physician. If you have questions about your health, you should consult your personal physician. This event is ...

Future Cardia, a medical device company, announced an expanded collaboration with remote cardiac monitoring company, Artella Solutions. Future Cardia is developing an implantable cardiac monitoring ...

Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

During spring 2005, we conducted an anonymous, Web-based survey of the members of the Heart Rhythm Society and the field representatives of the cardiac rhythm management divisions of two device ...

Relevant risk for interaction seen with cardiac implantable electronic devices; no signs of cardiac damage seen during testing. HealthDay News — When applied to cardiac implantable electronic devices ...

SAN DIEGO, CA—The observational BIO-LIBRA study, which enrolled nearly 50% women, has revealed important outcome differences by both sex and device type among patients with nonischemic cardiomyopathy ...